等待开盘 10-31 09:30:00 美东时间
-0.050
-1.22%
 华盛通
华盛通今日重点评级关注:Canaccord Genuity:维持ATAI Life Sciences"买入"评级,目标价从11美元升至14美元;麦格理:维持Cleanspark"跑赢大市"评级,目标价从20美元升至30美元
10-23 10:06
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
10-22 22:40
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
09-03 18:58
An announcement from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On Sep...
09-02 20:58
Mr. Raphi Levy, Alpha Tau Medical's CFO, will participate in five investor conferences in September 2025, including the Citi Biopharma Back to School Summit in Boston and the H.C. Wainwright Global Investment Conference in New York. Alpha Tau develops the Alpha DaRT technology, an innovative alpha-radiation therapy for solid tumors, with potential synergistic effects with other cancer treatments. The company emphasizes its commitment to advancing...
08-27 12:30
Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 13.04 percent. This is a 18.18 percent decrease over losses of $(0.11) per share
08-12 05:26
Alpha Tau Medical press release (NASDAQ:DRTS): Q2 GAAP EPS of -$0.22. As of June 30, 2025, the Company had cash and cash equivalents, short-term deposits and restricted deposits of $83.3 million, comp...
08-12 04:28
Alpha Tau (NASDAQ:DRTS) filed a prospectus to sale 3.46 million ordinary shares. The company will not receive any proceeds from the sale of ordinary shares by the selling shareholder. This prospectus ...
06-24 05:08
<br>Alpha Tau Medical Ltd.'s CFO, Raphi Levy, will present at the Jefferies Global Healthcare Conference on June 5, 2025, in New York, NY. The presentation will occur between 1:25 PM and 1:55 PM ET. Mr. Levy will also be available for individual investor meetings. Alpha Tau, an Israeli oncology company founded in 2016, develops Alpha DaRT<sup>®</sup>, an innovative alpha-radiation therapy for solid tumors. The technology, initially developed by r...
05-28 12:30
Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from
05-20 04:02